Skip to main content

Table 4 Summary of the exploratory analysis of plasma MF PK parameters (high dose [160 μg] versus medium dose [80 μg] on Day 1 and Day 14)

From: Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects

Ethnic group

PK parameter (unit)

Day 1

Day 14

Adjusted geometric mean

Adjusted geometric mean ratio (test/reference)

Adjusted geometric mean

Adjusted geometric mean ratio (test/reference)

IND/GLY/MF high-dose (test)

IND/GLY/MF medium-dose (reference)

Estimate (90% CI)

IND/GLY/MF high-dose (test)

IND/GLY/MF medium-dose (reference)

Estimate (90% CI)

Japanese

Cmax (pg/mL)

195 (n = 14)

104 (n = 16)

1.87 (1.73, 2.02)

264 (n = 14)

139 (n = 16)

1.91 (1.79, 2.02)

 

AUC0–24 h (hxpg/mL)

1700 (n = 14)

926 (n = 16)

1.84 (1.72, 1.97)

2520 (n = 14)

1260 (n = 16)

2.00 (1.92, 2.09)

Caucasian

Cmax (pg/mL)

193 (n = 15)

96.3 (n = 16)

2.00 (1.86, 2.16)

247 (n = 15)

121 (n = 16)

2.04 (1.93, 2.16)

 

AUC0–24 h (hxpg/mL)

1600 (n = 15)

784 (n = 16)

2.03 (1.90, 2.17)

2180 (n = 15)

1030 (n = 16)

2.13 (2.04, 2.21)

  1. Model: log (pk) = ethnic group + sequence + period + treatment + ethnic group * treatment, with random effects for subject and matched pair. Covariates were not included in this analysis. IND/GLY/MF medium-dose, IND/GLY/MF 150/50/80 μg o.d; IND/GLY/MF high-dose, IND/GLY/MF 150/50/160 μg o.d. AUC, area under curve; Cmax, maximum plasma concentration; IND/GLY/MF, indacaterol/glycopyrronium/mometasone furoate